TGF-β1 and endothelial/tissue injury with high-dose intravenous iron therapy in renal failure: Evidence or perception?

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 4, 2006, Pages 493-494

  Goździkiewicz, Joanna ^a   Borawski, Jacek ^a   Naumnik, Beata ^a   Rydzewska Rosołowska, Alicja ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; C REACTIVE PROTEIN; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN; TRANSFORMING GROWTH FACTOR BETA1; IRON; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DAMAGE; DOSE RESPONSE; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FAILURE; LETTER; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33748484661     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606293837     Document Type: Letter

References (9)

1. Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004;10:403.
2. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-β in blood: A complex problem. Cytokine Growth Factor Rev 2000;11:133.
3. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999; 10:99.
4. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003;41(suppl 1):S80.
5. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279.
6. Grainger DJ. Transforming growth factor-β and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;24:399.
7. Junker U, Haufe CC, Nuske K, et al. Elevated plasma TGF-β1 in renal diseases: Cause or consequence? Cytokine 2000;12:1084.
8. Harris H, Kirschenlohr H, Szabados N, Metcalfe J. Transforming growth factor-β1 inhibits thrombin activation of endothelial cells. Cytokine 2004;25:85.
9. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002;61:324.